Tag:
Omontys
Latest Headlines
Latest Headlines
FDA saw early reports of severe Omontys reactions: WSJ
The anemia drug Omontys triggered serious allergic reactions long before February's recall, The Wall Street Journal reports.
Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy
Without the fuel of Omontys sales, the small drugmaker is basically running on fumes.
Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy
In the wake of last month's Omontyx recall, Affymax is jettisoning three-fourths of its staff and considering bankruptcy. Without the fuel of Omontys sales, the small drugmaker is basically running on fumes. And it has to spend money to investigate the hypersensitivity reactions--and patient deaths--that triggered the recall. So, out comes the cost-cutting ax.
UPDATED: Affymax, Takeda pull Omontys after 3 deaths
Severe hypersensitivity reactions in Omontys patients prompted Affymax and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients.
Takeda, Affymax nail supply deal for Omontys anemia drug
Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.
Affymax banks $50M milestone on ESA drug approval
Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.
Affymax approval breaks Amgen's long anemia monopoly
Now that FDA has approved a new, independent amenia drug competitor, will Amgen's versions plummet?
Affymax breaks Amgen's anemia drug monopoly with ESA approval
Amgen has finally lost control of the U.S. market for anemia drugs needed to treat dialysis patients.
